Eli Lilly’s Dan Skovronsky on oral GLP-1, ‘slower ramp’ for Alzheimer’s and deals on ‘underappreciated’ assets
29 Nov 2023
Dan Skovronsky knows that any conversation about Eli Lilly is going to be largely about its work in obesity and Alzheimer’s. Although he wants everyone to know that the company is also excited about candidates in immunology and oncology, he’s also ready to take questions about those hottest topics head-on.
Speaking at an investor conference organized by Evercore ISI, Skovronsky — whose string of titles at Lilly includes executive vice president, chief scientific and medical officer, and president of Lilly Research Laboratories — addressed both high-level and granular questions about the pipeline and strategy.
Preview
Source: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.